What were the design, efficacy results, and safety outcomes of the 80‑week TRIUMPH‑2 Phase 3 trial of once‑weekly retatrutide in adults with type 2 diabetes who are obese (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with a weight‑related comorbidity?

TRIUMPH-2 Trial Summary

TRIUMPH-2 is an 80-week Phase 3 randomized, double-blind, placebo-controlled basket trial evaluating once-weekly subcutaneous retatrutide (a triple GIP/GLP-1/glucagon receptor agonist) versus placebo in adults with type 2 diabetes who are obese (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with weight-related comorbidities, conducted alongside healthy diet and physical activity interventions 1.

Trial Design

TRIUMPH-2 is part of a larger TRIUMPH clinical development program consisting of four Phase 3 trials enrolling over 5,800 participants total. The basket trial design uniquely allows simultaneous evaluation of retatrutide across multiple adiposity-related disease states 1.

Key Design Features:

• Population: Adults with type 2 diabetes and obesity or overweight with comorbidities
• Duration: 80 weeks
• Intervention: Once-weekly subcutaneous retatrutide versus placebo
• Comparator: Placebo with lifestyle modification
• Design: Multicenter, randomized, double-blind
• Primary Endpoint: Percent change in body weight from baseline
• Nested Protocols: Includes obstructive sleep apnea (OSA) and/or knee osteoarthritis (OA) protocols within the weight management trial 1

The basket trial design permits independent analysis of weight management, OSA, and OA studies while controlling type I error rate at α = 0.05, split between the overarching weight management trial and each nested basket trial 1.

Mechanism of Action

Retatrutide is a novel synthetic triple agonist that simultaneously activates three hormone receptors 1, 2:

• GIP receptor (GIPR): Glucose-dependent insulinotropic polypeptide
• GLP-1 receptor (GLP-1R): Glucagon-like peptide-1
• Glucagon receptor (GCGR): Glucagon

This triple agonism distinguishes retatrutide from dual GIP/GLP-1 agonists like tirzepatide, which has shown 15-20% body weight reductions 3.

Anticipated Efficacy Based on Related Evidence

While specific TRIUMPH-2 results are not yet published, related retatrutide trials provide context for expected outcomes:

Glycemic Control (from TRANSCEND-T2D-1 trial):

• HbA1c reductions of -1.69% to -1.94% across doses (4mg, 9mg, 12mg) versus -0.81% with placebo (all p<0.0001) 4
• Fasting glucose reductions up to -69.1 mg/dL 2
• No severe hypoglycemia reported 4

Weight Loss:

• In type 2 diabetes populations: -11.5% to -16.94% body weight reduction 4, 2
• In obesity without diabetes: up to -26.56% (24.15 kg) weight loss 2
• Significant reductions in BMI and waist circumference (up to -10.51 cm) 5

Cardiometabolic Benefits:

• Systolic blood pressure reduction: -9.88 mm Hg 5
• Diastolic blood pressure reduction: -3.88 mm Hg 5
• Liver fat reduction in MASLD: up to 86% 2

Safety Profile

Common Adverse Events: The most frequent adverse events are mild-to-moderate gastrointestinal symptoms that generally subside over time 4, 2:

• Nausea (most common)
• Vomiting
• Constipation
• Diarrhea

Study Discontinuation:

• Treatment discontinuation due to adverse events: 2-5% with retatrutide versus 0% with placebo 4
• 91% of participants completed the treatment period on study drug in TRANSCEND-T2D-1 4

Important Safety Considerations:

• Contraindicated in patients with personal or family history of medullary thyroid cancer or genetic testing positive for this condition 3
• Increased risk of gallbladder or biliary disease (consistent with GLP-1 RA class effect) 3
• Gastrointestinal adverse events likely related to rapid dose escalation and higher starting doses 2

Mortality: Two deaths occurred in related trials (both in retatrutide 4mg group), both deemed unrelated to study drug 4.

Clinical Context and Positioning

Current Guideline Recommendations: The ADA recommends GLP-1 RAs and dual GIP/GLP-1 RAs as preferred medications for overweight and obese patients with type 2 diabetes 3. Given retatrutide's triple agonist mechanism and superior weight loss compared to existing agents, it represents a potential advancement in this therapeutic class.

Risk Stratification Application: For adults with type 2 diabetes and obesity, treatment selection should consider cardiovascular and kidney risk stratification 6:

• Lower risk: Weight loss may be prioritized
• Moderate to higher risk: Cardiovascular and kidney outcomes become increasingly important
• Retatrutide's position will depend on cardiovascular outcomes data (currently lacking)

Common Pitfalls and Patient Counseling

To Minimize Gastrointestinal Side Effects:

• Eat smaller meals
• Drink plenty of water
• Increase dietary fiber
• Eat slowly and stop when feeling full
• Avoid high-fat or spicy foods
• Moderate alcohol and carbonated beverages 3

Monitoring Requirements:

• Immediate discontinuation if severe abdominal pain develops (pancreatitis concern) 3
• Screen for personal/family history of medullary thyroid cancer before initiation 3
• Monitor for gallbladder/biliary disease symptoms 3

Program Status

The TRIUMPH program is designed to assess retatrutide's safety and efficacy for adults with obesity and two common complications—obstructive sleep apnea and osteoarthritis—by recruiting participants with shared disease exposures 1. TRIUMPH-2 specifically targets the type 2 diabetes population within this broader basket trial framework.